Lund­beck sounds taps on an­oth­er CNS drug, re­treat­ing from a mine field still oc­cu­pied by a Mer­ck team

Lund­beck has snipped an­oth­er clin­i­cal-stage branch of its CNS re­search, dump­ing a schiz­o­phre­nia pro­gram af­ter de­ter­min­ing that their ther­a­py would have no pos­i­tive in­flu­ence on …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER